Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CDXC

CDXC - ChromaDex Corp Stock Price, Fair Value and News

2.61USD-0.27 (-9.38%)Market Closed

Market Summary

CDXC
USD2.61-0.27
Market Closed
-9.38%

CDXC Stock Price

View Fullscreen

CDXC RSI Chart

CDXC Valuation

Market Cap

217.6M

Price/Earnings (Trailing)

-61.66

Price/Sales (Trailing)

2.62

EV/EBITDA

-17.6

Price/Free Cashflow

47.04

CDXC Price/Sales (Trailing)

CDXC Profitability

Operating Margin

60.98%

EBT Margin

-19.88%

Return on Equity

-12.19%

Return on Assets

-6.52%

Free Cashflow Yield

2.13%

CDXC Fundamentals

CDXC Revenue

Revenue (TTM)

83.2M

Rev. Growth (Yr)

-1.79%

Rev. Growth (Qtr)

4.52%

CDXC Earnings

Earnings (TTM)

-3.5M

Earnings Growth (Yr)

74.13%

Earnings Growth (Qtr)

-531.58%

Breaking Down CDXC Revenue

Last 7 days

13.0%

Last 30 days

-6.8%

Last 90 days

-25.4%

Trailing 12 Months

72.9%

How does CDXC drawdown profile look like?

CDXC Financial Health

Current Ratio

2.52

CDXC Investor Care

Shares Dilution (1Y)

0.76%

Diluted EPS (TTM)

-0.05

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202483.2M000
202377.3M80.9M83.4M83.6M
202270.0M69.1M68.8M72.0M
202159.6M62.0M65.1M67.4M
202050.6M54.8M56.9M59.3M
201935.0M38.3M42.3M46.3M
201824.4M28.0M30.0M31.6M
201719.2M16.0M18.1M21.2M
201622.6M23.9M21.6M21.7M
201517.5M19.7M21.9M22.0M
201410.9M12.0M13.5M15.3M
201312.2M12.2M11.3M10.2M
20127.4M8.1M9.9M11.6M
20117.7M7.8M8.0M8.1M
20100007.6M

Tracking the Latest Insider Buys and Sells of ChromaDex Corp

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 01, 2023
gerber brianna
bought
7,050
1.41
5,000
chief financial officer
Sep 06, 2023
champion river ventures ltd
bought
-
-
3,467,780
-
Aug 12, 2023
gerber brianna
acquired
-
-
22,436
chief financial officer
Jun 12, 2023
jaksch frank l jr
bought
11,830
1.69
7,000
-
May 31, 2023
fried robert n
bought
9,940
1.42
7,000
chief executive officer
May 25, 2023
rubin steven d
bought
10,220
1.46
7,000
-
Sep 30, 2022
chau hoi shuen solina holly
bought
1,200,000
1.25
960,000
-
Sep 30, 2022
fried robert n
bought
100,000
1.25
80,000
cheif executive officer
Jun 16, 2022
chau hoi shuen solina holly
bought
99,877
1.6636
60,037
-
Mar 16, 2022
fried robert n
bought
54,000
2.16
25,000
ceo

1–10 of 33

Which funds bought or sold CDXC recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 09, 2024
LAZARD ASSET MANAGEMENT LLC
new
-
43,000
43,000
-%
May 16, 2024
JANE STREET GROUP, LLC
added
421
731,693
794,257
-%
May 15, 2024
TWO SIGMA SECURITIES, LLC
new
-
69,081
69,081
-%
May 15, 2024
ICONIQ Capital, LLC
unchanged
-
2,657,530
4,511,310
0.08%
May 15, 2024
Brevan Howard Capital Management LP
new
-
167,130
167,130
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
1,011
335
348
-%
May 15, 2024
BOOTHBAY FUND MANAGEMENT, LLC
sold off
-100
-213,120
-
-%
May 15, 2024
Cubist Systematic Strategies, LLC
new
-
31,323
31,323
-%
May 15, 2024
Man Group plc
new
-
61,057
61,057
-%
May 15, 2024
Squarepoint Ops LLC
reduced
-41.1
38,368
126,884
-%

1–10 of 47

Are Funds Buying or Selling CDXC?

Are funds buying CDXC calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CDXC
No. of Funds

Unveiling ChromaDex Corp's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Sep 07, 2023
champion river ventures ltd
10.58%
7,940,937
SC 13D/A
Oct 19, 2022
societe des produits nestle s.a.
5.11%
3,816,794
SC 13G
Oct 03, 2022
champion river ventures ltd
11.21%
7,940,937
SC 13D/A
Oct 03, 2022
pioneer step holdings ltd
9.77%
6,917,783
SC 13D/A
May 20, 2022
pioneer step holdings ltd
8.72%
5,957,783
SC 13D/A
May 20, 2022
shing li ka
9.51%
6,500,937
SC 13D/A
Feb 11, 2022
li ka shing (global) foundation
5.08%
3,467,778
SC 13G/A
Feb 11, 2022
yong rong (hk) asset management ltd
8.52%
5,819,802
SC 13G/A
Sep 21, 2021
chau hoi shuen solina holly
8.74%
5,957,783
SC 13D/A
Sep 20, 2021
chau hoi shuen solina holly
8.74%
5,957,783
SC 13D/A

Recent SEC filings of ChromaDex Corp

View All Filings
Date Filed Form Type Document
Jun 25, 2024
8-K
Current Report
Jun 24, 2024
8-K
Current Report
Jun 24, 2024
4
Insider Trading
Jun 24, 2024
4
Insider Trading
Jun 24, 2024
4
Insider Trading
Jun 24, 2024
4
Insider Trading
Jun 24, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
Jun 21, 2024
4
Insider Trading
May 08, 2024
8-K
Current Report

Peers (Alternatives to ChromaDex Corp)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
47.1B
6.8B
-17.23% -2.46%
-7.89
6.87
-64.45% -224.75%
33.0B
2.0B
67.01% 29.40%
-99.43
16.48
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
15.9B
2.5B
0.02% -1.58%
77.55
6.45
13.74% 186.89%
14.0B
3.8B
4.74% -0.56%
18.76
3.71
8.58% 129.81%
MID-CAP
5.0B
107.9M
-2.22% 48.86%
-9.2
48.09
54.84% -28.31%
4.7B
524.1M
-9.01% -54.24%
-11.31
9.01
394.93% 39.61%
4.0B
251.0M
18.93% 13.89%
-13.55
16
73.58% -86.73%
3.5B
240.7M
14.65% -16.72%
-7.42
12.77
-1.03% -213.92%
2.9B
813.8M
17.43% -31.75%
-1.7K
3.58
56.43% 98.83%
1.8B
996.6M
-22.65% 38.54%
-4.56
1.82
-26.66% 65.49%
SMALL-CAP
1.9B
411.3M
4.82% 27.42%
29.58
4.68
60.38% -34.49%
570.7M
881.7K
6.14% 580.25%
-16.91
481.06
-77.61% 33.36%
286.3M
4.2M
13.80% 73.74%
-2.29
68.83
-66.30% 48.24%
18.6M
2.1M
-12.55% 263.94%
-0.8
7.61
-13.45% 69.54%

ChromaDex Corp News

Latest updates
Simply Wall St10 hours ago
StockNews.com3 months ago

ChromaDex Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue4.5%22,15321,19619,49520,32322,55620,99617,06316,73217,25917,75917,30817,69914,68315,44514,18015,28714,34513,08912,05311,10110,048
Cost Of Revenue5.3%8,6978,2597,5267,9679,0388,9806,8566,6906,7276,8916,7306,8895,4496,0245,7266,1996,0345,6245,3044,8474,747
Gross Profit4.0%13,45612,93711,96912,35613,51812,01610,20710,04210,53210,86810,57810,8109,2349,4218,4549,0888,3117,4656,7496,2545,301
Operating Expenses8.3%14,18713,10513,11614,67215,48613,46013,27216,42918,26416,18419,41916,36416,59615,50212,65012,77514,20116,32513,63713,43413,673
  S&GA Expenses3.4%6,7406,5206,0356,0097,8746,1875,8688,0218,2378,6417,2216,2326,2586,3195,2234,9594,4475,1084,6264,3084,174
  R&D Expenses80.8%2,0951,1591,2411,3651,1931,2791,2241,2451,0781,0459961,0047878158418959191,1391,0441,0691,168
EBITDA Margin0.7%-0.18*-0.18*-0.18*-0.19*-0.20*-0.22*-0.23*-0.23*-0.22*-0.23*-0.24*-0.25*---------
Interest Expenses-15.2%23928218812566.0026.00-5.00-10.00-8.00-10115.0012.0019.0016.0019.0024.0012.00-42.0031457535.00
EBT Margin-0.5%-0.20*-0.20*-0.20*-0.20*-0.21*-0.23*-0.24*-0.24*-0.24*-0.25*-0.25*-0.27*---------
Net Income-531.6%-492114-959-2,191-1,902-1,418-985-6,397-7,740-5,325-8,856-5,566-7,381-6,097-4,215-3,711-5,902-8,853-7,202-7,755-8,337
Net Income Margin28.2%-0.04*-0.06*-0.08*-0.08*-0.14*-0.23*-0.30*-0.41*-0.39*-0.40*-0.43*-0.38*---------
Free Cashflow-51.4%3006173883,2322,760-368-3,780-3,872-7,238-4,984-5,959-7,935---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-1.6%54.0055.0053.0053.0054.0054.0046.0047.0053.0058.0060.0066.0069.0038.0037.0042.0036.0040.0043.0045.0042.00
  Current Assets-1.1%49.0050.0047.0046.0047.0047.0038.0039.0045.0049.0053.0058.0063.0032.0031.0036.0029.0034.0036.0038.0035.00
    Cash Equivalents0.9%28.0027.0027.0026.0023.0020.0013.0017.0021.0028.0033.0039.0045.0017.0015.0019.0014.0019.0019.0020.0019.00
  Inventory-14.0%12.0015.0013.0012.0012.0015.0016.0016.0015.0014.0013.0012.0013.0012.0011.0012.0011.0012.0010.0011.009.00
  Net PPE-----------3.003.003.003.003.003.004.004.004.004.004.00
Liabilities-5.2%25.0027.0026.0026.0026.0025.0025.0026.0027.0026.0025.0024.0025.0022.0018.0020.0019.0020.0016.0029.0021.00
  Current Liabilities-5.7%19.0021.0019.0019.0018.0018.0017.0018.0019.0018.0018.0016.0020.0016.0013.0016.0014.0015.0011.0024.0016.00
Shareholder's Equity1.7%29.0028.0027.0027.0028.0029.0021.0021.0026.0032.0035.0042.0044.0016.0019.0022.0017.0020.0027.0015.0021.00
  Retained Earnings-0.3%-190-190-190-189-187-185-184-183-176-168-163-154-149-141-135-131-127-121-113-105-98.09
  Additional Paid-In Capital0.4%220219218217215214205204203201199197193158155153144142140121119
Shares Outstanding0.2%75.0075.0075.0075.0075.0075.0068.0068.0068.0068.0067.0066.00---------
Float----81.00---79.00---474---190---190-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-51.4%3006174283,2802,792-328-3,740-3,832-7,198-4,944-5,919-7,895-5,40522.00-3,845-1,556-5,221-610-7,760-9,021-3,048
  Share Based Compensation-5.1%9841,0371,1171,3241,2731,3261,2291,2961,8881,4731,8221,6161,2841,7781,5741,7111,8731,6981,6861,7592,029
Cashflow From Investing-95.2%-41.00-21.00-26.00-5.00-91.00-172-52.00-85.00-25.00-2.00-96.00-265-46.0016.00-59.00-102-20.00272-156-69.00-296
Cashflow From Financing81.6%-14.00-76.00-3.00-10.00-1.007,679-18.00-4.00-3.0063.003392,24733,4451,1814926,94037.002717,0359,52355.00
  Buy Backs----------------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CDXC Income Statement

2024-03-31
Unaudited Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Sales, net$ 22,153$ 22,556
Cost of sales8,6979,038
Gross profit13,45613,518
Operating expenses:  
Sales and marketing6,7407,874
Research and development2,0951,193
General and administrative5,3526,419
Total operating expenses14,18715,486
Operating loss(731)(1,968)
Nonoperating income:  
Interest income, net23966
Net loss$ (492)$ (1,902)
Basic loss per common share attributable to ChromaDex Corporation (in dollars per share)$ (0.01)$ (0.03)
Diluted loss per common share attributable to ChromaDex Corporation (in dollars per share)$ (0.01)$ (0.03)
Basic weighted average common shares outstanding (in shares)75,23074,796
Diluted weighted average common shares outstanding (in shares)75,23074,796

CDXC Balance Sheet

2024-03-31
Unaudited Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents, including restricted cash of $152 for both periods presented$ 27,565$ 27,325
Trade receivables, net of allowances of $87 and $68, respectively; Including receivables from Related Party of $2.7 million and $2.8 million, respectively6,6045,234
Inventories12,49514,525
Prepaid expenses and other assets2,3122,450
Total current assets48,97649,534
Leasehold improvements and equipment, net2,0002,137
Intangible assets, net472510
Right-of-use assets, net2,2262,400
Other long-term assets405383
Total assets54,07954,964
Current liabilities  
Accounts payable7,89910,232
Accrued expenses10,4659,493
Current maturities of operating lease obligations850691
Current maturities of finance lease obligations1111
Customer deposits227195
Total current liabilities19,45220,622
Deferred revenue3,3113,311
Operating lease obligations, less current maturities2,3562,563
Finance lease obligations, less current maturities912
Total liabilities25,12826,508
Commitments and Contingencies (Note 10)
Stockholders' Equity  
Common stock, $0.001 par value; authorized 150,000 shares; 75,153 shares and 74,981 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively7575
Additional paid-in capital219,829218,845
Accumulated deficit(190,952)(190,460)
Cumulative translation adjustments(1)(4)
Total stockholders' equity28,95128,456
Total liabilities and stockholders' equity$ 54,079$ 54,964
CDXC
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.
 CEO
 WEBSITEchromadex.com
 INDUSTRYBiotechnology
 EMPLOYEES113

ChromaDex Corp Frequently Asked Questions


What is the ticker symbol for ChromaDex Corp? What does CDXC stand for in stocks?

CDXC is the stock ticker symbol of ChromaDex Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ChromaDex Corp (CDXC)?

As of Thu Jul 11 2024, market cap of ChromaDex Corp is 217.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CDXC stock?

You can check CDXC's fair value in chart for subscribers.

What is the fair value of CDXC stock?

You can check CDXC's fair value in chart for subscribers. The fair value of ChromaDex Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of ChromaDex Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CDXC so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is ChromaDex Corp a good stock to buy?

The fair value guage provides a quick view whether CDXC is over valued or under valued. Whether ChromaDex Corp is cheap or expensive depends on the assumptions which impact ChromaDex Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CDXC.

What is ChromaDex Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 11 2024, CDXC's PE ratio (Price to Earnings) is -61.66 and Price to Sales (PS) ratio is 2.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CDXC PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ChromaDex Corp's stock?

In the past 10 years, ChromaDex Corp has provided -0.04 (multiply by 100 for percentage) rate of return.